ProBioGen Launches Their Lentivirus Packaging Cell Line Lenti.RiGHT™

ProBioGen announced the launch of their lentivirus (LV) packaging cell line Lenti.RiGHT™ as a new platinum standard for LV production at this year's PEGS Boston 2023. The lentivirus production platform is based on HEK293 packaging cells stably transfected with all necessary viral components. Dr. Volker Sandig, Chief Scientific Officer at ProBioGen discussed the advantages and results of the platform in his presentation.

Lentiviral vectors dominate the manufacturing of the CAR-T cells. The production of the lentiviruses is typically based on transient transfection where 4 GMP-grade bacterial plasmids have to be manufactured and co-introduced at bioreactor scale. The whole process is complex, not very robust, and difficult to scale.

"With our Lenti.RiGHT platform we have developed a new standard for efficient large-scale lentivirus production and CAR-T manufacturing. It enables an inducible, scalable, and efficient production of high-titer lentiviral particles for gene transfer applications," explained Sandig.

About Lenti.RiGHT

The LV production cell line Lenti.RiGHT is based on HEK293 modified at ProBioGen to grow in a chemically defined medium (no animal components) in suspension to enable easy scale-up.

The main features are the stable integration of gag-pol, rev, and VSV-G using the transposase system DirectedLuck®. In addition, Lenti.RiGHT enables an inducible and efficient production of lentiviral particles with titers between 10⁷ and 10⁸ transducing units (TU) per ml and tightly-regulated expression of cytotoxic genes.

Lenti.RiGHT is applied in ProBioGen's services for clients and is also licensable for in-house work.